Cargando…
Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision
AIM: To compute the uncertainty of time‐in‐ranges, such as time in range (TIR), time in tight range (TITR), time below range (TBR) and time above range (TAR), to evaluate glucose control and to determine the minimum duration of a trial to achieve the desired precision. MATERIALS AND METHODS: Four fo...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518626/ https://www.ncbi.nlm.nih.gov/pubmed/34212483 http://dx.doi.org/10.1111/dom.14483 |
_version_ | 1784584267977719808 |
---|---|
author | Camerlingo, Nunzio Vettoretti, Martina Sparacino, Giovanni Facchinetti, Andrea Mader, Julia K. Choudhary, Pratik Del Favero, Simone |
author_facet | Camerlingo, Nunzio Vettoretti, Martina Sparacino, Giovanni Facchinetti, Andrea Mader, Julia K. Choudhary, Pratik Del Favero, Simone |
author_sort | Camerlingo, Nunzio |
collection | PubMed |
description | AIM: To compute the uncertainty of time‐in‐ranges, such as time in range (TIR), time in tight range (TITR), time below range (TBR) and time above range (TAR), to evaluate glucose control and to determine the minimum duration of a trial to achieve the desired precision. MATERIALS AND METHODS: Four formulas for the aforementioned time‐in‐ranges were obtained by estimating the equation's parameters on a training set extracted from study A (226 subjects, ~180 days, 5‐minute Dexcom G4 Platinum sensor). The formulas were then validated on the remaining data. We also illustrate how to adjust the parameters for sensors with different sampling rates. Finally, we used study B (45 subjects, ~365 days, 15‐minute Abbott Freestyle Libre sensor) to further validate our results. RESULTS: Our approach was effective in predicting the uncertainty when time‐in‐ranges are estimated using n days of continuous glucose monitoring (CGM), matching the variability observed in the data. As an example, monitoring a population with TIR = 70%, TITR = 50%, TBR = 5% and TAR = 25% for 30 days warrants a precision of ±3.50%, ±3.68%, ±1.33% and ±3.66%, respectively. CONCLUSIONS: The presented approach can be used to both compute the uncertainty of time‐in‐ranges and determine the minimum duration of a trial to achieve the desired precision. An online tool to facilitate its implementation is made freely available to the clinical investigator. |
format | Online Article Text |
id | pubmed-8518626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-85186262021-10-21 Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision Camerlingo, Nunzio Vettoretti, Martina Sparacino, Giovanni Facchinetti, Andrea Mader, Julia K. Choudhary, Pratik Del Favero, Simone Diabetes Obes Metab Original Articles AIM: To compute the uncertainty of time‐in‐ranges, such as time in range (TIR), time in tight range (TITR), time below range (TBR) and time above range (TAR), to evaluate glucose control and to determine the minimum duration of a trial to achieve the desired precision. MATERIALS AND METHODS: Four formulas for the aforementioned time‐in‐ranges were obtained by estimating the equation's parameters on a training set extracted from study A (226 subjects, ~180 days, 5‐minute Dexcom G4 Platinum sensor). The formulas were then validated on the remaining data. We also illustrate how to adjust the parameters for sensors with different sampling rates. Finally, we used study B (45 subjects, ~365 days, 15‐minute Abbott Freestyle Libre sensor) to further validate our results. RESULTS: Our approach was effective in predicting the uncertainty when time‐in‐ranges are estimated using n days of continuous glucose monitoring (CGM), matching the variability observed in the data. As an example, monitoring a population with TIR = 70%, TITR = 50%, TBR = 5% and TAR = 25% for 30 days warrants a precision of ±3.50%, ±3.68%, ±1.33% and ±3.66%, respectively. CONCLUSIONS: The presented approach can be used to both compute the uncertainty of time‐in‐ranges and determine the minimum duration of a trial to achieve the desired precision. An online tool to facilitate its implementation is made freely available to the clinical investigator. Blackwell Publishing Ltd 2021-07-21 2021-11 /pmc/articles/PMC8518626/ /pubmed/34212483 http://dx.doi.org/10.1111/dom.14483 Text en © 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Camerlingo, Nunzio Vettoretti, Martina Sparacino, Giovanni Facchinetti, Andrea Mader, Julia K. Choudhary, Pratik Del Favero, Simone Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision |
title | Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision |
title_full | Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision |
title_fullStr | Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision |
title_full_unstemmed | Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision |
title_short | Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision |
title_sort | design of clinical trials to assess diabetes treatment: minimum duration of continuous glucose monitoring data to estimate time‐in‐ranges with the desired precision |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518626/ https://www.ncbi.nlm.nih.gov/pubmed/34212483 http://dx.doi.org/10.1111/dom.14483 |
work_keys_str_mv | AT camerlingonunzio designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision AT vettorettimartina designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision AT sparacinogiovanni designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision AT facchinettiandrea designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision AT maderjuliak designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision AT choudharypratik designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision AT delfaverosimone designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision AT designofclinicaltrialstoassessdiabetestreatmentminimumdurationofcontinuousglucosemonitoringdatatoestimatetimeinrangeswiththedesiredprecision |